down arrow

Taysha Gene Therapies, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US8776191061
USD
5.06
1 (24.63%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
CorMedix, Inc.
Poseida Therapeutics, Inc.
Monte Rosa Therapeutics, Inc.
Lineage Cell Therapeutics, Inc.
Fate Therapeutics, Inc.
Akoya Biosciences, Inc.
Verastem, Inc.
Taysha Gene Therapies, Inc.
AlloVir, Inc.
Reneo Pharmaceuticals, Inc.
Synlogic, Inc.
Why is Taysha Gene Therapies, Inc. ?
1
The company has declared negative results for the last 4 consecutive quarters
  • OPERATING CASH FLOW(Y) Lowest at USD -82.11 MM
  • NET SALES(9M) At USD 6.31 MM has Grown at -22.36%
  • OPERATING PROFIT(Q) Lowest at USD -26.48 MM
2
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 58.82%, its profits have fallen by -5.5%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Taysha Gene Therapies, Inc. for you?

High Risk, Medium Return

Absolute
Risk Adjusted
Volatility
Taysha Gene Therapies, Inc.
93.87%
0.17
100.12%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
73.68%
EBIT Growth (5y)
3.80%
EBIT to Interest (avg)
-63.95
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.31
Sales to Capital Employed (avg)
0.26
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
13.49
EV to EBIT
-8.01
EV to EBITDA
-8.12
EV to Capital Employed
-38.70
EV to Sales
92.80
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-149.22%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company
NET PROFIT(HY)

Higher at USD -45.25 MM

RAW MATERIAL COST(Y)

Fallen by -18.09% (YoY

-11What is not working for the Company
OPERATING CASH FLOW(Y)

Lowest at USD -82.11 MM

NET SALES(9M)

At USD 6.31 MM has Grown at -22.36%

OPERATING PROFIT(Q)

Lowest at USD -26.48 MM

PRE-TAX PROFIT(Q)

Lowest at USD -25.15 MM

NET PROFIT(Q)

Lowest at USD -25.15 MM

Here's what is working for Taysha Gene Therapies, Inc.
Raw Material Cost
Fallen by -18.09% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Taysha Gene Therapies, Inc.
Net Sales
At USD 6.31 MM has Grown at -22.36%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very negative

Net Sales (USD MM)

Operating Cash Flow
Lowest at USD -82.11 MM and Fallen
In each year in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Operating Profit
Lowest at USD -26.48 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is negative

Operating Profit (USD MM)

Pre-Tax Profit
Lowest at USD -25.15 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Pre-Tax Profit
At USD -25.15 MM has Fallen at -22.43%
over average net sales of the previous four periods of USD -20.54 MM
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit
Lowest at USD -25.15 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is negative

Net Profit (USD MM)

Net Profit
At USD -25.15 MM has Fallen at -22.43%
over average net sales of the previous four periods of USD -20.54 MM
MOJO Watch
Near term Net Profit trend is negative

Net Profit (USD MM)

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."